Chong Kun Dang Bio Files China Application for CU-20101
Chong Kun Dang Bio submitted a biologics license application for CU-20101 to China’s drug regulator, targeting a launch in the second half of 2027.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Chong Kun Dang Bio said on August 18 that it had filed a biologics license application for its botulinum toxin product CU-20101 with China’s National Medical Products Administration. One report specifies that the filing was made on August 14 and identifies the 100-unit product name as Tmverse injection.
The company is aiming for a Chinese launch in the second half of 2027. It described China as the world’s second-largest botulinum toxin market after the United States and as a strategic market expected to expand alongside medical aesthetics.
What the filing changes
Submitting the application moves CU-20101 from clinical development into China’s regulatory review pathway. The filing starts the formal process toward the company’s stated commercialization target, but it is an application rather than an approval or launch.
Chong Kun Dang Bio conducted a Chinese phase 3 trial involving 554 participants. Kormedi characterized the product’s effect as equivalent to Botox, while the reports’ summaries do not supply the trial endpoints, numerical results, safety findings, or the regulator’s review timetable.
Limits and patient context
The event concerns a regulatory filing for future market entry, not a new treatment option currently available to patients in China. The company’s second-half 2027 launch date remains a target tied to the regulatory process.
A filing does not determine how an individual patient may respond. Botulinum toxin decisions should account for individual variation, possible side effects, and recovery considerations, and patients should consult a qualified physician about whether a specific product and treatment plan are appropriate.
Questions for a consultation
Patients considering botulinum toxin treatment can ask which product is being proposed, whether it is authorized in their location, and what evidence supports its intended use. They can also ask how the clinician will tailor the treatment to their medical history and goals.
The consultation should also cover expected side effects, warning signs, follow-up, and recovery guidance for the proposed treatment. These answers must come from the treating clinician because the regulatory filing reports do not establish patient-specific instructions.
Frequently asked questions
Has CU-20101 been approved in China?
No approval was announced. Chong Kun Dang Bio submitted a biologics license application to China’s National Medical Products Administration, beginning the regulatory process toward its stated launch target.
When is CU-20101 expected to launch in China?
Chong Kun Dang Bio is targeting the second half of 2027. That date is a company target associated with the regulatory process, not a confirmed availability date.
How large was the China phase 3 trial?
Chong Kun Dang Bio conducted the Chinese phase 3 trial in 554 participants. The published summaries do not include detailed endpoints, numerical outcomes, or safety results.
Botulinum toxin consultation checklist
- Which botulinum toxin product are you proposing, and is it authorized here?
- What evidence supports the intended use for my treatment goal?
- How could my medical history affect individual variation and side effects?
- What recovery guidance, warning signs, and follow-up plan should I know?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
